Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alpha-synuclein A53T AAV is an adeno-associated viral (AAV) vector used primarily in preclinical research to model Parkinson's disease. It delivers the human SNCA gene carrying the A53T missense mutation, which is associated with early-onset familial Parkinson's disease. Upon stereotaxic injection into specific brain regions like the substantia nigra pars compacta (SNpc), the vector induces the overexpression of mutant alpha-synuclein, leading to protein aggregation, dopaminergic neuronal loss, and mitochondrial dysfunction. This model is essential for investigating the molecular mechanisms of synucleinopathies and evaluating potential therapeutic interventions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alpha-synuclein A53T AAV.